obiadminpharma
Company will hold the Investor Conference
1.Date of the investor conference:2016/06/05 2.Time of the investor conference:2:00 p.m.(Taiwan Time) 3.Location of the investor conference: 11F., No.97, Sec. 2, Dunhua S. Rd., Da’an Dist., Taipei City 106, Taiwan …
The company states the media’s reports on the related matters of American Society of Clinical Oncology (ASCO).
1.Date of occurrence of the event:2016/05/29 2.Company name: OBI Pharma, Inc. 3.Relationship to the Company (please enter ”head office” or ”affiliatecompany”): The Company head office 4.Reciprocal shareholding ratios: N/A 5.Name …
Media reports that Michael Chang, the chairman of the company, Amy Huang, the general manager and the staffs, six people in total, were guaranteed pending summons for alleged insider trading.
1.Date of occurrence of the event:2016/05/26 2.Company name: OBI Pharma, Inc. 3.Relationship to the Company (please enter ”head office” or ”affiliatecompany”): The Company head office 4.Reciprocal shareholding ratios: N/A 5.Name …
Publication of the Breast Cancer Study Abstract to be presented at ASCO 2016
1.Date of occurrence of the event:2016/05/19 2.Name of the company: OBI Pharma, Inc. 3.Relationship to the Company (please enter ”head office” or ”affiliate company”): The Company head office 4.Reciprocal shareholding …
OBI’s Abstract at ASCO 2016: Randomized Phase 2/3 Trial of Active Immunotherapy With OPT-822/OPT-821 in Patients With Metastatic Breast Cancer
Background: Globo H is a glycolipid that is highly expressed in breast cancer (BC). Active immunotherapy with OPT-822, a Globo H-KLH conjugate, and the adjuvant OPT-821 in two phase 1 …
OBI Pharma to Present New Data at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting
Oral Presentation Highlights the Results of a Phase II/III Trial of the Investigational Immunotherapy OBI-822/OBI-821 in Patients with Metastatic Breast Cancer TAIPEI, TAIWAN, May 19, 2016 – OBI Pharma, Inc., …
Board Intentions to apply for long-term fund-raising plan
1.Date of the board of directors resolution:2016/05/13 2.Source of capital increase funds:The intention to issue not more than 20 million ordinary shares in domestic cash fundraising or a capital increase …
Supplementary notice on a company board resolution for the upcoming 2016 Annual Shareholders’ Meeting
1.Date of the board of directors resolution:2016/05/13 2.Date for convening the shareholders’ meeting:2016/06/27 3.Location for convening the shareholders’ meeting: Masterlink Securities Education and Training Center (Da-an District, Taipei Dun Hua …
Company Position Statement Regarding Recent Investigation of Senior Executives
OBI Pharma strongly denies allegations of insider trading. Since March 2016, the Shi-Lin District Prosecutor’s Office has been investigating whether senior OBI executives sold shares with foreknowledge of the results …
Company reports outsider suspected of “rumor mongering” intended to manipulate company’s stock, and plans to take legal action against “NEXT Magazine”
1.Parties to the legal matter, name of the court, disposing agency, and reference/case numbers of relevant documents: Plaintiff: OBI Pharma, Inc. Defendants: (1)An individual spreading false rumors and manipulating company …